Research
Metabolic adaptation
Orforglipron treatment resulted in significant improvements in waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels compared to placebo.
Orforglipron may improve several cardiovascular and metabolic risk factors in obese adults.
StrongSupportsmedium confidence
Waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels significantly improved with orforglipron treatment as compared with placebo.
Why this rating
Based on a phase 3 randomized controlled trial design.
Source
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Sean Wharton et al. · New England Journal of Medicine · 2025
DOI 10.1056/nejmoa2511774
rct · n=3127Cited 69×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In adults with obesity, treatment with 36 mg of orforglipron for 72 weeks led to a mean body weight reduction of -11.2%, significantly greater than the -2.1% reduction with placebo (P<0.001).Strong
- 54.6% of patients in the orforglipron 36-mg group achieved a weight reduction of 10% or more, compared to 12.9% in the placebo group.Strong
Related findings · Metabolic adaptation
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →